INM Stock Overview
A clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
InMed Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.24 |
| 52 Week High | US$0.78 |
| 52 Week Low | US$0.12 |
| Beta | 0.73 |
| 11 Month Change | 20.18% |
| 3 Month Change | 98.21% |
| 1 Year Change | -43.36% |
| 33 Year Change | -99.36% |
| 5 Year Change | -99.87% |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M
Sep 26InMed Pharma announces $6M private placement
Sep 09InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens
Jul 25InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement
Jul 13InMed To Acquire Rare Cannabinoid Manufacturer BayMedica
Jul 02InMed's INM-755 CBN cream did not introduce any delay in normal wound healing
Jan 08Shareholder Returns
| INM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -31.6% | -3.7% | -1.6% |
| 1Y | -43.4% | 17.2% | 30.8% |
Return vs Industry: INM underperformed the US Pharmaceuticals industry which returned 17.2% over the past year.
Return vs Market: INM underperformed the US Market which returned 30.8% over the past year.
Price Volatility
| INM volatility | |
|---|---|
| INM Average Weekly Movement | 56.0% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: INM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INM's weekly volatility has increased from 31% to 56% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Eric Adams | www.inmedpharma.com |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products.
InMed Pharmaceuticals Inc. Fundamentals Summary
| INM fundamental statistics | |
|---|---|
| Market cap | US$3.48m |
| Earnings (TTM) | -US$7.68m |
| Revenue (TTM) | US$4.60m |
0.7x
P/S Ratio-0.4x
P/E RatioIs INM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INM income statement (TTM) | |
|---|---|
| Revenue | US$4.60m |
| Cost of Revenue | US$3.50m |
| Gross Profit | US$1.10m |
| Other Expenses | US$8.78m |
| Earnings | -US$7.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 23.94% |
| Net Profit Margin | -166.94% |
| Debt/Equity Ratio | 0% |
How did INM perform over the long term?
See historical performance and comparison